Craig M Crews
Overview
Explore the profile of Craig M Crews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
10738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Samarasinghe K, An E, Genuth M, Chu L, Holley S, Crews C
RSC Chem Biol
. 2022 Sep;
3(9):1144-1153.
PMID: 36128504
Dysregulated transcription factors (TFs) that rewire gene expression circuitry are frequently identified as key players in disease. Although several TFs have been drugged with small molecules, the majority of oncogenic...
12.
Swartzel J, Bond M, Pintado-Urbanc A, Daftary M, Krone M, Douglas T, et al.
ACS Chem Biol
. 2022 Jun;
17(7):1789-1798.
PMID: 35749470
The RNA decapping scavenger protein, DcpS, has recently been identified as a dependency in acute myeloid leukemia (AML). The potent DcpS inhibitor RG3039 attenuates AML cell viability, and shRNA knockdown...
13.
Li K, Crews C
Chem Soc Rev
. 2022 Jun;
51(12):5214-5236.
PMID: 35671157
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of one ligand that binds to a protein of interest (POI) and another that can recruit an E3 ubiquitin ligase. The chemically-induced proximity...
14.
Nalawansha D, Li K, Hines J, Crews C
J Am Chem Soc
. 2022 Mar;
144(12):5594-5605.
PMID: 35311258
Targeted protein degradation (TPD) by PROTACs is a promising strategy to control disease-causing protein levels within the cell. While TPD is emerging as an innovative drug discovery paradigm, there are...
15.
Bekes M, Langley D, Crews C
Nat Rev Drug Discov
. 2022 Jan;
21(3):181-200.
PMID: 35042991
Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. In the...
16.
Chen P, Hu Z, An E, Okeke I, Zheng S, Luo X, et al.
ACS Chem Biol
. 2021 Nov;
16(12):2808-2815.
PMID: 34780684
Protein phosphorylation, which regulates many critical aspects of cell biology, is dynamically governed by kinases and phosphatases. Many diseases are associated with dysregulated hyperphosphorylation of critical proteins, such as retinoblastoma...
17.
Hu Z, Crews C
Chembiochem
. 2021 Sep;
23(2):e202100270.
PMID: 34494353
Proteolysis-targeting chimeras (PROTACs), an emerging paradigm-shifting technology, hijacks the ubiquitin-proteasome system for targeted protein degradation. PROTACs induce ternary complexes between an E3 ligase and POI, and this induced proximity leads...
18.
Bond M, Crews C
RSC Chem Biol
. 2021 Jul;
2(3):725-742.
PMID: 34212149
With the discovery of PROteolysis TArgeting Chimeras (PROTACs) twenty years ago, targeted protein degradation (TPD) has changed the landscape of drug development. PROTACs have evolved from cell-impermeable peptide-small molecule chimeras...
19.
20.
Jaime-Figueroa S, Bond M, Vergara J, Swartzel J, Crews C
J Org Chem
. 2021 May;
86(12):8479-8488.
PMID: 34047555
A novel, facile, and expeditious two-step synthesis of 3,4-unsubstituted isoquinolin-1(2)-ones from a Suzuki cross-coupling between 2-halobenzonitriles and commercially available vinyl boronates followed by platinum-catalyzed nitrile hydrolysis and cyclization is described.